SRR627425
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1398157 | GTEX | — | 0.965 |
| 2 | SRR1452056 | GTEX | — | 0.957 |
| 3 | MNG555 | — | — | 0.957 |
| 4 | SRR602927 | GTEX | — | 0.955 |
| 5 | SRR4195666 | — | — | 0.955 |
| 6 | BS_J71N7D09 | medulloblastoma | — | 0.951 |
| 7 | MNG598 | — | — | 0.951 |
| 8 | SRR1341008 | GTEX | — | 0.951 |
| 9 | SRR1323130 | GTEX | — | 0.949 |
| 10 | msclc569389_S35.txt | — | cohortMD1 | 0.946 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.331 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.242 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.236 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.096 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.066 | Inavolisib | — uncovered |